StemCyte (4178) reported revenue of NT$33 million for Oct 2026, +16.0% year on year and +7.6% from the previous month. Revenue for Jan–Oct 2026 was NT$312.6 million (+4.0% year on year).
Year-on-year revenue growth: 7 months in a row. →
In Oct 2026, it ranked No. 115 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$33 million | +16.0% | +7.6% |
| Sep 2026 | NT$30.7 million | +28.2% | -3.9% |
| Aug 2026 | NT$32 million | +9.0% | -1.4% |
| Jul 2026 | NT$32.4 million | +13.7% | -4.1% |
| Jun 2026 | NT$33.8 million | +4.9% | +12.0% |
| May 2026 | NT$30.2 million | +5.0% | -7.7% |
| Apr 2026 | NT$32.7 million | +29.7% | +17.6% |
| Mar 2026 | NT$27.8 million | -27.1% | -4.5% |
| Feb 2026 | NT$29.1 million | -13.6% | -6.0% |
| Jan 2026 | NT$30.9 million | -4.5% | +13.1% |
| Dec 2025 | NT$27.4 million | -29.1% | -11.4% |
| Nov 2025 | NT$30.9 million | -3.3% | +8.4% |
| Oct 2025 | NT$28.5 million | -13.3% | +18.9% |
| Sep 2025 | NT$24 million | -24.6% | -18.3% |
| Aug 2025 | NT$29.3 million | -5.4% | +2.8% |
| Jul 2025 | NT$28.5 million | -18.8% | -11.5% |
| Jun 2025 | NT$32.2 million | +17.6% | +12.2% |
| May 2025 | NT$28.7 million | -6.6% | +14.1% |
| Apr 2025 | NT$25.2 million | -29.0% | -33.9% |
| Mar 2025 | NT$38.1 million | +33.6% | +13.2% |
| Feb 2025 | NT$33.7 million | +9.0% | +3.9% |
| Jan 2025 | NT$32.4 million | +14.4% | -16.1% |
| Dec 2024 | NT$38.6 million | +28.2% | +20.9% |
| Nov 2024 | NT$31.9 million | +12.5% | -2.8% |
| Oct 2024 | NT$32.9 million | — | +3.4% |
Jan–Oct 2026 cumulative: NT$312.6 million (+4.0% YoY)
Other Biotech & Medical companies
Compare with peers: StemCyte vs PEC / StemCyte vs Lotus Pharm / StemCyte vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16